Related references
Note: Only part of the references are listed.Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
Edward S. Kim et al.
LANCET (2008)
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancer
Roy S. Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Angiogenesis inhibitor therapies: Focus on kidney toxicity and hypertension
Hassane Izzedine et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2007)
Vandetanib in advanced NSCLC: an ongoing clinical evaluation program
Wilfried E. Eberhardt et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis
Roy S. Herbst et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2007)
Cancer statistics, 2007
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Toxicities of antiangiogenic therapy in non-small-cell lung cancer
Roy S. Herbst
CLINICAL LUNG CANCER (2006)
Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer
Tania Cufer et al.
ANTI-CANCER DRUGS (2006)
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
N Thatcher et al.
LANCET (2005)
Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors
SN Holden et al.
ANNALS OF ONCOLOGY (2005)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
ZD6474 - a novel inhibitor of VEGFR and EGFR tyrosine kinase activity
AJ Ryan et al.
BRITISH JOURNAL OF CANCER (2005)
EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib
W Pao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Minireview: RET: Normal and abnormal functions
M Santoro et al.
ENDOCRINOLOGY (2004)
Overview of the tolerability of gefitinib (IRESSA (TM)) monotherapy - Clinical experience in non-small-cell lung cancer
B Forsythe et al.
DRUG SAFETY (2004)
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer
DH Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer - A randomized trial
MG Kris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer
M Fukuoka et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
JH Schiller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Clinical trial designs for the early clinical development of therapeutic cancer vaccines
RM Simon et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Clinical trial designs for cytostatic agents: Are new approaches needed?
EL Korn et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
